Financial Ratios Attovia Therapeutics, Inc.
Stocks
ATTO
US04987L1026
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 20.80 USD | +2.92% |
|
+4.73% | - |
| 08-14 | Attovia Therapeutics Insider Bought Shares Worth $10,285,000, According to a Recent SEC Filing | MT |
| 08-05 | Attovia Therapeutics, Inc.(NasdaqGM:ATTO) added to NASDAQ Composite Index | CI |
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Profitability | ||
Return on Assets | - | -34.6 |
Return on Total Capital | - | -38.48 |
Return On Equity % | - | -56.95 |
Return on Common Equity | - | 78.6 |
Margin Analysis | ||
Gross Profit Margin % | - | -3.91K |
SG&A Margin | - | 1.06K |
EBITDA Margin % | - | -4.92K |
EBITA Margin % | - | -4.97K |
EBIT Margin % | - | -4.97K |
Income From Continuing Operations Margin % | - | -4.49K |
Net Income Margin % | - | -4.49K |
Net Avail. For Common Margin % | - | -4.49K |
Normalized Net Income Margin | - | -2.81K |
Levered Free Cash Flow Margin | - | -2.98K |
Unlevered Free Cash Flow Margin | - | -3.01K |
Asset Turnover | ||
Asset Turnover | - | 0.01 |
Fixed Assets Turnover | - | 0.24 |
Short Term Liquidity | ||
Current Ratio | 9.39 | 14.2 |
Quick Ratio | 8.98 | 13.92 |
Operating Cash Flow to Current Liabilities | -4.54 | -5.38 |
Average Days Payable Outstanding | - | 25.92 |
Long Term Solvency | ||
Total Debt/Equity | - | 3.49 |
Total Debt / Total Capital | - | 3.37 |
LT Debt/Equity | - | 2.22 |
Long-Term Debt / Total Capital | - | 2.14 |
Total Liabilities / Total Assets | 19.02 | 9.1 |
Total Debt / EBITDA | - | -0.08 |
Net Debt / EBITDA | 1.68 | 2.22 |
Total Debt / (EBITDA - Capex) | - | -0.08 |
Net Debt / (EBITDA - Capex) | 1.61 | 2.14 |
Growth Over Prior Year | ||
Gross Profit, 1 Yr. Growth % | - | 55.93 |
EBITDA, 1 Yr. Growth % | - | 60.9 |
EBITA, 1 Yr. Growth % | - | 61.62 |
EBIT, 1 Yr. Growth % | - | 61.62 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 52.33 |
Net Income, 1 Yr. Growth % | - | 52.33 |
Normalized Net Income, 1 Yr. Growth % | - | 52.33 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 36.2 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 143.2 |
Total Assets, 1 Yr. Growth % | - | 116.24 |
Tangible Book Value, 1 Yr. Growth % | - | 129.44 |
Common Equity, 1 Yr. Growth % | - | 129.44 |
Cash From Operations, 1 Yr. Growth % | - | 68.97 |
Capital Expenditures, 1 Yr. Growth % | - | 30.53 |
- Stock Market
- Stocks
- ATTO Stock
- Financials Attovia Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















